Policy Updates Medical Policy & Clinical GuidelinesCommercialOctober 31, 2022

Transition to AIM Specialty Health Perirectal Hydrogel Spacer for Prostate Radiotherapy Clinical Appropriateness Guideline

Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem.

This communication applies to the Commercial, Medicaid, and Medicare Advantage programs from Empire.

 

Effective November 6, 2022, Empire will transition the Clinical Criteria for medical necessity review of perirectal hydrogel spacer to the AIM Specialty Health®* (AIM) Perirectal Hydrogel Spacer for Prostate Radiotherapy Clinical Appropriateness Guideline.

 

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

  • Access AIM’s ProviderPortalSM directly at https://providerportal.com. Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
  • Access AIM via Availity* at availity.com.

 

For questions related to guidelines, contact AIM via email at aim.guidelines@aimspecialtyhealth.com.

 

Additionally, you may access and download a copy of the current and upcoming guidelines here.

* AIM Specialty Health is an independent company providing some utilization review services on behalf of Empire. Availity, LLC is an independent company providing administrative support services on behalf of Empire.


NYBCBS-CDCRCM-006043-22-CPN5953

PUBLICATIONS: November 2022 Newsletter